<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149015</url>
  </required_header>
  <id_info>
    <org_study_id>FNF015</org_study_id>
    <nct_id>NCT04149015</nct_id>
  </id_info>
  <brief_title>Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer</brief_title>
  <official_title>A Phase II Trial of Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single center, phase II study, to evaluate the effectiveness and safety of
      POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the neoadjuvant
      therapy for patients with advanced/metastatic gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete and subtotal regression (TRG1a/b by Becker)</measure>
    <time_frame>after 4 cycles (each cycle is 14 days) + surgery; i.e. after 12 weeks in total</time_frame>
    <description>Pathological complete and subtotal regression (TRG1a/b by Becker). TRG1a/b is defined as &lt; 10% residual tumor per tumor bed based on evaluation of the resected esophagogastric specimen in the primary by a pathologist.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>POF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel ,oxaliplatin,fluorouracil</intervention_name>
    <description>A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.</description>
    <arm_group_label>POF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years old;

          -  Patients must have histologically or cytologically confirmed resectable gastric or
             gastroesophageal junction (GEJ) adenocarcinoma without distant metastases. GEJ
             adenocarcinoma may be classified according to Siewert's classification type I, II, or
             III

          -  Patients may have received no prior chemotherapy.

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1;

          -  An expected survival of ≥ 3 months;

          -  Major organ function has to meet the following criteria; (1) For results of blood
             routine test:

          -  Hemoglobin (HB) ≥ 80g / L,

          -  ANC(absolute neutrophil count) ≥ 1.5 × 109 / L,

          -  PLT(blood platelet) ≥ 75 × 109 / L, (2) For results of biochemical tests:

          -  BLT（total bilirubin） ≤ 1.25 times the upper limit of normal (ULN),

          -  ALT(Alanine aminotransferase) and AST(aspartate aminotransferase ) ≤ 2.5 × ·ULN, liver
             metastases, if any, the ALT and AST≤ 5 × ULN,

          -  Serum Cr（creatinine）≤1ULN, Endogenous creatinine clearance rate ＞50ml/min;

          -  The patient has a PT（prothrombintime） (INR international normalized ratio) &lt; or = to
             1.5 and an PTT（Partial Thromboplastin Time）&lt; than or = to 3 seconds above the upper
             limits of normal if the patientia t is not on anticoagulation. ·If a patient is on
             full-dose anticoagulants, the following criteria should be met for enrollment:

          -  The patient must have an in-range INR (usually between 2 and 3) on a stable dose of
             warfarin or on stable dose of LMW(Low molecular weight) heparin

          -  The patient must not have active bleeding or pathological conditions that carry high
             risk of bleeding (e.g. tumor involving major vessels, known varices)

          -  Pregnancy test (serum or urine) has to be performed for woman of childbearing age
             within 7 days before enrolment and the test result must be negative.

          -  Men and women of childbearing potential must be willing to consent to using effective
             contraception while on treatment and for at least 3 months thereafter.

          -  Ability to understand informed consent and signing of written informed consent
             document prior to initiation of protocol therapy.

        Exclusion Criteria:

          1. Subjects with second primary cancer, besides dermatoma, primary cancer of nervous
             system, non-metastatic prostatic neoplasms.

          2. Gastrointestinal bleeding.

          3. women of child-bearing age must take a negative result of serum pregnancy test within
             7 days prior to enrollment, and willing to use appropriate methods of contraception
             during the trial and 12 weeks after the last trial drug. For men, who willing to use
             appropriate methods of contraception during the trial and 12 weeks after the last
             trial drug.

          4. Ongoing corticosteroid drug therapy.

          5. With a history of previous severe cardiovascular disease: over grade-two myocardial
             ischemia or myocardial infarction, congestive hert filure, and myocardial infarction
             or coagulopathy within 6 months.

          6. Having got apoplexy or cardiovascular accident within 6 months.

          7. Having got severe peripheral vascular disease in clinics.

          8. Subjects who have a history of psychiatric substance abuse and cannot quit or have
             mental disorders.

          9. The researchers concluded that the subjects were not suitable for clinic trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

